StockSelector.com
  Research, Select, & Monitor Thursday, June 21, 2018 9:41:38 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Revance Therapeutics, Inc.$30.75($.55)(1.76%)

  Quote | Chart | Valuations | Sentiment | Industry | News | Earnings | Analysts | More...

Your Target?

Revance Therapeutics, Inc. has an overall rank of 6294 out of 7208 stocks based on 7 positive rankings and 9 negative rankings.

Positive Rankings
Estimated Revenue Growth
Revance Therapeutics rank is 22
Target Prices
The average analysts' target price is $45.00 for Revance Therapeutics using target prices set or adjusted within the past 90 days. Among companies with recent target prices and with the average above the current stock price, Revance Therapeutics is ranked 91.
Debt-to-Equity
Revance Therapeutics rank is 177
Highest Cash Growth
Revance Therapeutics rank is 340
Low Put/Call
Revance Therapeutics has a low Put/Call ratio of 0.33 on all open interest of options expiring in the next 90 days. A low put-to-call ratio indicates there are more bullish investors than bearish investors for the stock. Among companies with a low Put/Call Ratio, Revance Therapeutics is ranked 794.
10 Day Gain
Revance Therapeutics rank is 1156
90 Day Gain
Revance Therapeutics rank is 2382
Negative Rankings
Price-to-Sales
Revance Therapeutics rank is 8
Negative Net Margin
Revance Therapeutics rank is 14
Negative Revenue Growth
Revance Therapeutics rank is 201
Negative ROA
Revance Therapeutics rank is 619
Negative ROE
Revance Therapeutics rank is 646
High/Dropping MACD
The MACD remains positive, but is dropping... suggesting a possible near-term correction. Of companies with a positive, but declining MACD, Revance Therapeutics is ranked 719.
Down EPS Surprise
Revance Therapeutics missed the consensus earnings estimate when it last reported quarterly earnings.
Price-to-Book
Revance Therapeutics rank is 1314
High vPut/Call
Revance Therapeutics has a high Put/Call ratio of 0.54 on active options expiring within the next 90 days. A high put-to-call ratio indicates there are more bearish investors than bullish investors for the stock. Among companies with a high Put/Call Ratio, Revance Therapeutics is ranked 1384.







Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2018 StockSelector.com. All rights reserved.